Pharmacia Diagnostics, Device Operations Are Outside Pfizer Drug Focus
This article was originally published in The Gray Sheet
Executive Summary
Pfizer's strategy to exit the medical device business in the late 1990s to focus on its core pharmaceutical business portends a similar fate for Pharmacia's device and diagnostics operations following the completion of the companies' $60 bil. consolidation